MedTrace Logo

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2018-12-11

Study results available
· View outcomes & findings →

Summary

Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.

Conditions

  • Seborrheic Keratosis (SK)

Interventions

DRUG

A-101 25%

Low Dose Concentration of A-101 applied to one of 4 Target Lesions

DRUG

A-101 32.5%

Mid Dose Concentration of A-101 applied to one of 4 Target Lesions

DRUG

A-101 40%

High Dose Concentration A-101 applied to one of 4 Target Lesions

DRUG

A-101 Vehicle

Placebo applied to one of 4 Target Lesions

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Janet Dubois, MD · Derm Research, PLLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-22
Primary Completion
2014-02-25
Completion
2014-02-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01986920 on ClinicalTrials.gov